Suppr超能文献

PG16 与 PG9 嵌合体的晶体结构:两种有效中和 HIV-1 的具有四级特异性的抗体的结构-功能分析。

Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3027, USA.

出版信息

J Virol. 2010 Aug;84(16):8098-110. doi: 10.1128/JVI.00966-10. Epub 2010 Jun 10.

Abstract

HIV-1 resists neutralization by most antibodies. Two somatically related human antibodies, PG9 and PG16, however, each neutralize 70 to 80% of circulating HIV-1 isolates. Here we present the structure of the antigen-binding fragment of PG16 in monoclinic and orthorhombic lattices at 2.4 and 4.0 A, respectively, and use a combination of structural analysis, paratope dissection, and neutralization assessment to determine the functional relevance of three unusual PG9/PG16 features: N-linked glycosylation, extensive affinity maturation, and a heavy chain-third complementarity-determining region (CDR H3) that is one of the longest observed in human antibodies. Glycosylation extended off the side of the light chain variable domain and was not required for neutralization. The CDR H3 formed an axe-shaped subdomain, which comprised 42% of the CDR surface, with the axe head looming approximately 20 A above the other combining loops. Comprehensive sets of chimeric swaps between PG9 and PG16 of light chain, heavy chain, and CDR H3 were employed to decipher structure-function relationships. Chimeric swaps generally complemented functionally, with differences in PG9/PG16 neutralization related primarily to residue differences in CDR H3. Meanwhile, chimeric reversions to genomic V genes showed isolate-dependent effects, with affinity maturation playing a significant role in augmenting neutralization breadth (P = 0.036) and potency (P < 0.0001). The structural and functional details of extraordinary CDR H3 and extensive affinity maturation provide insights into the neutralization mechanism of and the elicitation pathway for broadly neutralizing antibodies like PG9 and PG16.

摘要

HIV-1 可抵抗大多数抗体的中和作用。然而,两种体细胞相关的人类抗体 PG9 和 PG16 可分别中和 70%至 80%的循环 HIV-1 分离株。在此,我们报告了 PG16 的抗原结合片段在单斜和正交晶格中的结构,分辨率分别为 2.4 和 4.0Å,并结合结构分析、表位剖析和中和评估来确定三个不寻常的 PG9/PG16 特征的功能相关性:N 连接糖基化、广泛的亲和力成熟和重链第三互补决定区(CDR H3),这是在人类抗体中观察到的最长之一。糖基化从轻链可变结构域的侧面延伸出来,对中和作用没有必需性。CDR H3 形成了一个斧头形状的亚结构域,占 CDR 表面的 42%,斧头的头部悬在其他结合环上方约 20Å。我们采用了 PG9 和 PG16 的轻链、重链和 CDR H3 的广泛嵌合体置换来破译结构-功能关系。嵌合体置换通常在功能上互补,PG9/PG16 中和作用的差异主要与 CDR H3 中的残基差异有关。同时,对基因组 V 基因的嵌合体回复显示出与分离株相关的效应,亲和力成熟在增强中和广度(P = 0.036)和效力(P < 0.0001)方面发挥了重要作用。CDR H3 的结构和功能细节为了解 PG9 和 PG16 等广泛中和抗体的中和机制和诱导途径提供了深入的认识。

相似文献

2
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11483-8. doi: 10.1073/pnas.1004600107. Epub 2010 Jun 2.
6
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.
7
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.
8
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.
9
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.

引用本文的文献

1
Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.
PLoS Pathog. 2024 Sep 9;20(9):e1012042. doi: 10.1371/journal.ppat.1012042. eCollection 2024 Sep.
5
mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
Science. 2024 May 17;384(6697):eadk0582. doi: 10.1126/science.adk0582.
6
Unveiling the multifaceted landscape of N-glycosylation in antibody variable domains: Insights and implications.
Int J Biol Macromol. 2024 Feb;257(Pt 1):128362. doi: 10.1016/j.ijbiomac.2023.128362. Epub 2023 Nov 28.
8
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Science. 2022 Dec 2;378(6623):eadd6502. doi: 10.1126/science.add6502.
10
Adjuvants influence the maturation of VRC01-like antibodies during immunization.
iScience. 2022 Nov 2;25(11):105473. doi: 10.1016/j.isci.2022.105473. eCollection 2022 Nov 18.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies.
Viruses. 2009 Dec;1(3):802-17. doi: 10.3390/v1030802. Epub 2009 Nov 6.
3
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11483-8. doi: 10.1073/pnas.1004600107. Epub 2010 Jun 2.
4
Therapeutic antibodies, vaccines and antibodyomes.
MAbs. 2010 May-Jun;2(3):347-56. doi: 10.4161/mabs.2.3.11779. Epub 2010 May 14.
7
Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1529-34. doi: 10.1073/pnas.0909680107. Epub 2010 Jan 4.
8
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. doi: 10.1107/S0907444909042073. Epub 2009 Dec 21.
10
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
Science. 2009 Nov 20;326(5956):1123-7. doi: 10.1126/science.1175868.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验